PharmAust Limited announced it will undertake an interim analysis of preliminary biomarkers and efficacy markers on completion of dosing of the last patient of Cohort 2 in its MND trial. This interim analysis constitutes an approved protocol amendment to the initial approved protocol as recommended by the Principal Investigator. Treatment-related changes from baseline in this safety, tolerability, pharmacokinetic and preliminary, efficacy study will include an analysis of functional rating scales, quality of life and cognitive assessment.

Furthermore, prognostic indicators and several disease-related biomarkers will be measured. Following this protocol amendment, PharmAust will continue with the MPL dose escalation for Cohorts level 3 and then 4 (subject to Safety Committee reviews). This process may facilitate determining the optimum dose level or range for a Phase 2 trial.